These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35630075)

  • 1. Genetic Variants of Complement Factor H Y402H (rs1061170), C2 R102G (rs2230199), and C3 E318D (rs9332739) and Response to Intravitreal Anti-VEGF Treatment in Patients with Exudative Age-Related Macular Degeneration.
    Kubicka-Trząska A; Żuber-Łaskawiec K; Dziedzina S; Sanak M; Romanowska-Dixon B; Karska-Basta I
    Medicina (Kaunas); 2022 May; 58(5):. PubMed ID: 35630075
    [No Abstract]   [Full Text] [Related]  

  • 2. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
    Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
    Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of complement factor B rs4151667 (L9H) polymorphisms and its interactional role with CFH Y402H and C3 rs2230199 (R102G) risk variants in age-related macular degeneration: a case control study.
    Roshanipour N; Laleh MG; Bonyadi M; Bonyadi MHJ; Soheilian M; Javadzadeh A; Yaseri M
    BMC Ophthalmol; 2020 Aug; 20(1):323. PubMed ID: 32762675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint association of complement component 3 and CC-cytokine ligand2 (CCL2) or complement component 3 and CFH polymorphisms in age-related macular degeneration.
    Bonyadi M; Jabbarpoor Bonyadi MH; Yaseri M; Mohammadian T; Fotouhi N; Javadzadeh A; Soheilian M
    Ophthalmic Genet; 2017; 38(4):365-370. PubMed ID: 28095095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of genetic base in the treatment of age-related macular degeneration.
    Gourgouli K; Gourgouli I; Tsaousis G; Spai S; Niskopoulou M; Efthimiopoulos S; Lamnissou K
    Int Ophthalmol; 2020 Apr; 40(4):985-997. PubMed ID: 31916060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N; Shen Y; Yu CY; Wang SQ; Tong JP
    Acta Ophthalmol; 2016 Jun; 94(4):334-45. PubMed ID: 27151934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CFH Y402H and VEGF Polymorphisms and Anti-VEGF Treatment Response in Exudative Age-Related Macular Degeneration.
    Kepez Yildiz B; Ozdek S; Ergun MA; Ergun S; Yaylacioglu Tuncay F; Elbeg S
    Ophthalmic Res; 2016; 56(3):132-8. PubMed ID: 27404493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.
    Brantley MA; Fang AM; King JM; Tewari A; Kymes SM; Shiels A
    Ophthalmology; 2007 Dec; 114(12):2168-73. PubMed ID: 18054635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.
    Roshanshad A; Moosavi SA; Arevalo JF
    Ophthalmic Res; 2024; 67(1):358-386. PubMed ID: 38754401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of genetic variants rs641153 (
    Neto JM; Viturino MG; Ananina G; Bajano FF; Costa SMDS; Roque AB; Borges GF; Franchi R; Rim PH; Medina FM; Costa FF; Melo MB; de Vasconcellos JP
    Exp Biol Med (Maywood); 2021 Nov; 246(21):2290-2296. PubMed ID: 34233521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the CFH Y402H Polymorphism with the 1-Year Response of Exudative AMD to Intravitreal Anti-VEGF Treatment in the Brazilian Population.
    Medina FMC; Motta AALD; Takahashi WY; Carricondo PC; Motta MMDS; Melo MB; Vasconcellos JPC
    Ophthalmic Res; 2019; 61(3):168-173. PubMed ID: 28641277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Single-Nucleotide Polymorphisms in Age-Related Macular Degeneration With Pseudodrusen: Secondary Analysis of Data From the Comparison of AMD Treatments Trials.
    Lin LY; Zhou Q; Hagstrom S; Maguire MG; Daniel E; Grunwald JE; Martin DF; Ying GS;
    JAMA Ophthalmol; 2018 Jun; 136(6):682-688. PubMed ID: 29801032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants in three genes and smoking show strong associations with susceptibility to exudative age-related macular degeneration in a Chinese population.
    Chu J; Zhou CC; Lu N; Zhang X; Dong FT
    Chin Med J (Engl); 2008 Dec; 121(24):2525-33. PubMed ID: 19187590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Islam AF; Guymer RH; Baird PN
    Ophthalmology; 2013 Aug; 120(8):1641-8. PubMed ID: 23582991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene polymorphisms associated with an increased risk of exudative age-related macular degeneration in a Spanish population.
    Gili P; Lloreda Martín L; Martín-Rodrigo JC; Kim-Yeon N; Modamio-Gardeta L; Fernández-García JL; Rebolledo-Poves AB; Gómez-Blazquez E; Pazos-Rodriguez R; Pérez-Fernández E; Velasco M
    Eur J Ophthalmol; 2022 Jan; 32(1):651-657. PubMed ID: 33765843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).
    Hagstrom SA; Ying GS; Pauer GJT; Sturgill-Short GM; Huang J; Callanan DG; Kim IK; Klein ML; Maguire MG; Martin DF;
    Ophthalmology; 2013 Mar; 120(3):593-599. PubMed ID: 23337555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
    Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Nischler C; Oberkofler H; Ortner C; Paikl D; Riha W; Lang N; Patsch W; Egger SF
    Acta Ophthalmol; 2011 Jun; 89(4):e344-9. PubMed ID: 21232084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noncoding variant in the complement factor H gene and risk of exudative age-related macular degeneration in a Chinese population.
    Cui L; Zhou H; Yu J; Sun E; Zhang Y; Jia W; Jiao Y; Snellingen T; Liu X; Lim A; Wang N; Liu N
    Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):1116-20. PubMed ID: 19850835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.